3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
NIH
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
2
Interventions
Carboplatin
542
Pemetrexed
392
pembrolizumab
372
Cisplatin
356
Paclitaxel
285
Docetaxel
240
Gemcitabine
168
Nivolumab
158
Erlotinib Hydrochloride
147
Bevacizumab
114
atezolizumab
104
osimertinib
99
durvalumab
92
Etoposide
90
Gefitinib
68
130-nm albumin-bound paclitaxel
65
Cetuximab
64
Ipilimumab
60
Drug Therapy
51
Topotecan
48
Injections
44
Afatinib
41
tislelizumab
40
Cyclophosphamide
39
Albumin-Bound Paclitaxel
37
Vinorelbine
36
Crizotinib
34
cemiplimab
31
icotinib
26
Radiotherapy
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
talactoferrin alfa
×
Thoracic
×
Clear all
NCT00707304
2012-08-21
FORTIS-M
Agennix
Phase 3
Completed
742 enrolled
NCT00706862
2012-03-15
FORTIS-C
Agennix
Phase 3
Unknown
1,100 enrolled